诺和诺德减肥药专利败诉,仿制药商胜出

新浪医药
Jul 25, 2025

诺和诺德与迈兰(Mylan)围绕减肥药Wegovy的专利大战进入终章。近日,法官在对诺和诺德关于Wegovy的专利主张进行全面审查后,判定该专利不符合受保护的必要标准。这一裁决有利于迈兰(Mylan),可继续推进减肥药的 仿制药 。由于迈兰即将推出Wegovy的仿制药,市场竞争有望压低价格,使更多人能够获得Wegovy“平替”。2022年,诺和诺德曾对迈兰提起诉讼,该案件最终与与特拉华州联邦法院的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10